DEPACON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPACON (DEPACON).
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
| Metabolism | Metabolized primarily via glucuronidation (CYP-independent) and beta-oxidation; less than 3% excreted unchanged in urine. |
| Excretion | Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%). |
| Half-life | 10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours. |
| Protein binding | 90–95% bound to albumin; binding is saturable and decreased in uremia, hypoalbuminemia, and in elderly patients. |
| Volume of Distribution | 0.13–0.23 L/kg; increases with age and obesity; small Vd indicates predominant distribution in plasma and extracellular fluid. |
| Bioavailability | Oral (immediate-release): ~100%; IV: 100%; rectal administration (not standard): approximately 80%. |
| Onset of Action | Oral (immediate-release): 3–5 days for maximal seizure control; IV loading dose produces therapeutic levels within minutes, with clinical effect within 1–2 hours. |
| Duration of Action | Approximately 8–12 hours for immediate-release oral and IV formulations; sustained-release formulations provide therapeutic effects for 24 hours. |
| Molecular Weight | 166.17 |
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 30%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce dose by 70%. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 30%; Child-Pugh C: reduce dose by 50%. |
| Pediatric use | 10-20 mg/kg/day IV or orally divided every 6-8 hours; maximum 40 mg/kg/day. |
| Geriatric use | Start at lowest dose (10 mg/kg/day) and titrate slowly; monitor renal function and adjust accordingly. |
| 1st trimester | Increased risk of neural tube defects and other congenital malformations; use only if benefits outweigh risks. |
| 2nd trimester | May cause fetal anticonvulsant syndrome; monitor for IUGR and hemorrhagic complications. |
| 3rd trimester | Neonatal hemorrhage risk due to vitamin K deficiency; administer vitamin K prophylactically. |
Clinical note
Comprehensive clinical and safety monograph for DEPACON (DEPACON).
| Placental transfer | Readily crosses the placenta; fetal levels approximate maternal levels. |
| Breastfeeding | Enters breast milk in low concentrations; generally considered compatible but monitor infant for drowsiness and poor feeding. |
| Lactation Rating |
■ FDA Black Box Warning
Hepatotoxicity: Cases of life-threatening hepatic failure, especially in children under 2 years and patients with mitochondrial disease; fatalities reported. Contraindicated in patients with known liver disease.
| Serious Effects |
Hypersensitivity to valproic acid or derivativesHepatic disease or significant hepatic dysfunctionUrea cycle disordersMitochondrial disease (e.g., Alpers-Huttenlocher syndrome)
| Precautions | Hepatotoxicity: Monitor liver function tests before and during therapy; discontinue if significant elevation., Pancreatitis: Rare but potentially fatal; discontinue if pancreatitis suspected., Hyperammonemic encephalopathy: Often in patients with urea cycle disorders or concomitant medications; monitor ammonia levels., Teratogenicity: Valproate exposure causes neural tube defects and neurodevelopmental disorders; avoid in women of childbearing potential unless ineffective alternatives., Thrombocytopenia and coagulation disorders: Platelet count and bleeding time monitoring recommended. |
| Food/Dietary | Take with food or milk to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase valproate levels. Limit intake of foods high in aspartame (may increase ammonia levels). Maintain adequate hydration to reduce risk of hyperammonemia. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Valproate (Depacon) is highly teratogenic. First trimester exposure is associated with a 3-4% risk of neural tube defects (spina bifida), as well as craniofacial defects, cardiac defects, and hypospadias. Second and third trimester exposure may be linked to neurodevelopmental disorders including autism spectrum disorder and low IQ. Risk is dose-dependent. |
| Fetal Monitoring | Maternal: Serum valproate concentrations, liver function tests, complete blood count, coagulation profile. Fetal: First trimester ultrasound and maternal serum alpha-fetoprotein (MSAFP) for neural tube defects; detailed fetal anatomical survey at 18-20 weeks; consider fetal echocardiography. Third trimester: fetal growth monitoring. |
| Fertility Effects | Valproate may cause menstrual irregularities, anovulation, and polycystic ovary syndrome (PCOS)-like changes, potentially impairing fertility. In males, reversible effects on semen quality (reduced motility, abnormal morphology) have been reported. Effects are generally reversible upon discontinuation. |
| Clinical Pearls | Depacon (valproate sodium) injection is a prodrug of valproic acid. For status epilepticus, administer IV push at 20 mg/kg, then 1-3 mg/kg/h infusion. Avoid in liver disease; monitor liver enzymes and ammonia. Also used off-label for migraine prophylaxis and bipolar disorder maintenance. |
| Patient Advice | Do not stop taking Depacon suddenly without consulting your doctor. · Avoid alcohol while using this medication. · Report any signs of liver injury (jaundice, abdominal pain, dark urine) or pancreatitis (severe abdominal pain, nausea, vomiting). · Depacon may cause dizziness or drowsiness; avoid driving until you know how it affects you. · If you are pregnant or planning to become pregnant, discuss risks; Depacon can cause birth defects. |